Small Molecule Targeted Cancer Therapy Market by Applications (Small Molecules [Small Molecule Cyclin-dependent Kinase Inhibitor, Small Molecule Tyrosine Kinase Inhibitor, and Small Molecule Proteasome Inhibitor], Monoclonal Antibodies [Fully Human Antibody, Chimeric Monoclonal Antibody, Humanized Monoclonal Antibody, and Humanized Monoclonal Antibody], and Small Molecule Drug Conjugates) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
The global small molecule targeted cancer therapy market size is projected to register a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to its huge adoption rate and minimum adverse effects of the therapy.
The small molecule targeted cancer therapy is a rapidly growing and widely adopted treatment process for targeted cancer patients. In general, patients tend to use several alternative drugs available in the market to treat the disease. However, rising patent expiry of the drugs such as Glivec of Novartis, is an immense opportunity for manufacturers to develop new targeted drugs, which act to prevent cancerous cell growth. Therapies such as conventional medications and chemotherapy are likely to destroy the cells and stop the cell growth rapidly. The small molecule targeted therapy destroy cancer cells with better efficiency and less side effects. There are various types of cancers such as prostate cancer, multiple myeloma, lymphoma, melanoma and breast cancer which are treated by this targeted therapy.
To increase the compliance and self-care ability to the patients who went through small molecule therapy, the International Society of Nurse in Cancer Care initiated Led Small Molecule Chemotherapy Patient Education Program, which is funded by Glaxo Smith Kline. Small molecules target the intra-cellular protein and spike the aperture of a tumor. Identification and purity of small molecule target cancer cells is certified due to purification, chemical synthesis, and molecular characterization techniques to make them effortless to reproduce. Antibodies are regulated intravenously, while small molecules can be orally regulated. Small molecules therapy if proven successful is expected to be another treatment for the cancer immunotherapy.
Market Trends, Drivers, Restraints, and Opportunities
- High prevalence rates of cancer and wide demand for advanced therapy method for cancer treatment are expected to boost the market growth.
- Wide availability of drugs and medications for the treatment of the disease is projected to propel the market expansion.
- Massive R&D activities by major healthcare players and major competitive of global players are estimated to expand the market growth.
- High cost of the treatment acts as a major challenge that can hamper the market expansion during the forecast period.
- Wide awareness of the treatment drugs and inclination of the targeted people regarding cancer diagnosis are anticipated to push the market growth.
Scope of the Report
The report on the global small molecule targeted cancer therapy market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Small Molecule Targeted Cancer Therapy Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2020 |
|
Historic Data |
2018–2019 |
|
Forecast Period |
2021–2028 |
|
Segmentation |
Applications (Small Molecules [Small Molecule Cyclin-dependent Kinase Inhibitor, Small Molecule Tyrosine Kinase Inhibitor, and Small Molecule Proteasome Inhibitor], Monoclonal Antibodies [Fully Human Antibody, Chimeric Monoclonal Antibody, Humanized Monoclonal Antibody, and Humanized Monoclonal Antibody], and Small Molecule Drug Conjugates) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Abbott Laboratories; Boehringer Ingelheim GmbH; Bayer HealthCare AG; Cytokinetics Inc.; Hospira Inc.; OncoGenex Pharmaceuticals Inc.; and GlaxoSmithKline PLC |
Market Segment Insights
Monoclonal antibodies segment is expected to grow at a rapid pace
Based on applications, the global small molecule targeted cancer therapy market is segregated into small molecules, monoclonal antibodies, and small molecule drug conjugates. The small molecules is further divided into small molecule cyclin-dependent kinase inhibitor, small molecule tyrosine kinase inhibitor, and small molecule proteasome inhibitor. The monoclonal antibodies is sub-classified as fully human antibody, chimeric monoclonal antibody, humanized monoclonal antibody, and humanized monoclonal antibody. The monoclonal antibodies segment is expected to grow at a rapid pace during the forecast period due to its huge adoption rates for the disease treatment. On the other hand, the small molecules segment is estimated to expand at a substantial growth rate during the forecast period owing to high precision and few side effects.
North America is anticipated to constitute a key market share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America accounted for a key share of the market in 2020 and is projected to exhibit a high CAGR during the forecast period owing to increasing incidences of cancer in the region. The market of Asia Pacific, however, is estimated to grow at a rapid pace during the forecast period due to growing infrastructure and various initiatives for awareness in people and for R&D activities in the region.
Segments
The global small molecule targeted cancer therapy market has been segmented on the basis of
Applications
- Small Molecules
- Small Molecule Cyclin-dependent Kinase Inhibitor
- Small Molecule Tyrosine Kinase Inhibitor
- Small Molecule Proteasome Inhibitor
- Monoclonal Antibodies
- Fully Human Antibody
- Chimeric Monoclonal Antibody
- Humanized Monoclonal Antibody
- Humanized Monoclonal Antibody
- Small Molecule Drug Conjugates
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Abbott Laboratories
- Boehringer Ingelheim GmbH
- Bayer HealthCare AG
- Cytokinetics Inc.
- Hospira Inc.
- OncoGenex Pharmaceuticals Inc.
- GlaxoSmithKline PLC
Competitive Landscape
Key players competing in the global small molecule targeted cancer therapy market are Abbott Laboratories; Boehringer Ingelheim GmbH; Bayer HealthCare AG; Cytokinetics Inc.; Hospira Inc.; OncoGenex Pharmaceuticals Inc.; and GlaxoSmithKline PLC. The main market players are continuously engaged in various development activities such as mergers and acquisitions, research and developments, investments for innovative products and collaborations to enhance their market position globally. BeiGene got its cancer drugs in clinic tests, listing poly ADP ribose polymerase inhibitor and a la ibrutinib, BRAF inhibitor.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Small Molecule Targeted Cancer Therapy Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Small Molecule Targeted Cancer Therapy Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Small Molecule Targeted Cancer Therapy Market - Supply Chain
4.5. Global Small Molecule Targeted Cancer Therapy Market Forecast
4.5.1. Small Molecule Targeted Cancer Therapy Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Small Molecule Targeted Cancer Therapy Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Small Molecule Targeted Cancer Therapy Market Absolute $ Opportunity
5. Global Small Molecule Targeted Cancer Therapy Market Analysis and Forecast by Region
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Region
5.2.2. Y-o-Y Growth Projections by Region
5.3. Small Molecule Targeted Cancer Therapy Market Size and Volume Forecast by Region
5.3.1. North America
5.3.2. Latin America
5.3.3. Europe
5.3.4. Asia Pacific
5.3.5. Middle East and Africa (MEA)
5.4. Absolute $ Opportunity Assessment by Region
5.5. Market Attractiveness/Growth Potential Analysis by Region
5.6. Global Small Molecule Targeted Cancer Therapy Demand Share Forecast, 2019-2026
6. North America Small Molecule Targeted Cancer Therapy Market Analysis and Forecast
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis by Country
6.1.2. Y-o-Y Growth Projections by Country
6.2. North America Small Molecule Targeted Cancer Therapy Market Size and Volume Forecast by Country
6.2.1. U.S.
6.2.2. Canada
6.3. Absolute $ Opportunity Assessment by Country
6.4. Market Attractiveness/Growth Potential Analysis
6.4.1. By Country
6.4.2. By Product Type
6.4.3. By Application
6.5. North America Small Molecule Targeted Cancer Therapy Demand Share Forecast, 2019-2026
7. Latin America Small Molecule Targeted Cancer Therapy Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.1.3. Latin America Average Pricing Analysis
7.2. Latin America Small Molecule Targeted Cancer Therapy Market Size and Volume Forecast by Country
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Absolute $ Opportunity Assessment by Country
7.4. Market Attractiveness/Growth Potential Analysis
7.4.1. By Country
7.4.2. By Product Type
7.4.3. By Application
7.5. Latin America Small Molecule Targeted Cancer Therapy Demand Share Forecast, 2019-2026
8. Europe Small Molecule Targeted Cancer Therapy Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Europe Average Pricing Analysis
8.2. Europe Small Molecule Targeted Cancer Therapy Market Size and Volume Forecast by Country
8.2.1. Germany
8.2.2. France
8.2.3. Italy
8.2.4. U.K.
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Absolute $ Opportunity Assessment by Country
8.4. Market Attractiveness/Growth Potential Analysis
8.4.1. By Country
8.4.2. By Product Type
8.4.3. By Application
8.5. Europe Small Molecule Targeted Cancer Therapy Demand Share Forecast, 2019-2026
9. Asia Pacific Small Molecule Targeted Cancer Therapy Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Asia Pacific Average Pricing Analysis
9.2. Asia Pacific Small Molecule Targeted Cancer Therapy Market Size and Volume Forecast by Country
9.2.1. China
9.2.2. Japan
9.2.3. South Korea
9.2.4. India
9.2.5. Australia
9.2.6. Rest of Asia Pacific (APAC)
9.3. Absolute $ Opportunity Assessment by Country
9.4. Market Attractiveness/Growth Potential Analysis
9.4.1. By Country
9.4.2. By Product Type
9.4.3. By Application
9.5. Asia Pacific Small Molecule Targeted Cancer Therapy Demand Share Forecast, 2019-2026
10. Middle East & Africa Small Molecule Targeted Cancer Therapy Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Middle East & Africa Average Pricing Analysis
10.2. Middle East & Africa Small Molecule Targeted Cancer Therapy Market Size and Volume Forecast by Country
10.2.1. Saudi Arabia
10.2.2. South Africa
10.2.3. UAE
10.2.4. Rest of Middle East & Africa (MEA)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Market Attractiveness/Growth Potential Analysis
10.4.1. By Country
10.4.2. By Product Type
10.4.3. By Application
10.5. Middle East & Africa Small Molecule Targeted Cancer Therapy Demand Share Forecast, 2019-2026
11. Competition Landscape
11.1. Global Small Molecule Targeted Cancer Therapy Market: Market Share Analysis
11.2. Small Molecule Targeted Cancer Therapy Distributors and Customers
11.3. Small Molecule Targeted Cancer Therapy Market: Competitive Dashboard
11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
11.4.1. Abbott Laboratories
11.4.2. Boehringer Ingelheim GmbH
11.4.3. Bayer HealthCare AG
11.4.4. Cytokinetics Inc.
11.4.5. Hospira Inc.
11.4.6. OncoGenex Pharmaceuticals Inc.
11.4.7. GlaxoSmithKline PLC
2. Assumptions and Acronyms Used
3. Research Methodology
4. Small Molecule Targeted Cancer Therapy Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Small Molecule Targeted Cancer Therapy Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Small Molecule Targeted Cancer Therapy Market - Supply Chain
4.5. Global Small Molecule Targeted Cancer Therapy Market Forecast
4.5.1. Small Molecule Targeted Cancer Therapy Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Small Molecule Targeted Cancer Therapy Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Small Molecule Targeted Cancer Therapy Market Absolute $ Opportunity
5. Global Small Molecule Targeted Cancer Therapy Market Analysis and Forecast by Region
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Region
5.2.2. Y-o-Y Growth Projections by Region
5.3. Small Molecule Targeted Cancer Therapy Market Size and Volume Forecast by Region
5.3.1. North America
5.3.2. Latin America
5.3.3. Europe
5.3.4. Asia Pacific
5.3.5. Middle East and Africa (MEA)
5.4. Absolute $ Opportunity Assessment by Region
5.5. Market Attractiveness/Growth Potential Analysis by Region
5.6. Global Small Molecule Targeted Cancer Therapy Demand Share Forecast, 2019-2026
6. North America Small Molecule Targeted Cancer Therapy Market Analysis and Forecast
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis by Country
6.1.2. Y-o-Y Growth Projections by Country
6.2. North America Small Molecule Targeted Cancer Therapy Market Size and Volume Forecast by Country
6.2.1. U.S.
6.2.2. Canada
6.3. Absolute $ Opportunity Assessment by Country
6.4. Market Attractiveness/Growth Potential Analysis
6.4.1. By Country
6.4.2. By Product Type
6.4.3. By Application
6.5. North America Small Molecule Targeted Cancer Therapy Demand Share Forecast, 2019-2026
7. Latin America Small Molecule Targeted Cancer Therapy Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.1.3. Latin America Average Pricing Analysis
7.2. Latin America Small Molecule Targeted Cancer Therapy Market Size and Volume Forecast by Country
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Absolute $ Opportunity Assessment by Country
7.4. Market Attractiveness/Growth Potential Analysis
7.4.1. By Country
7.4.2. By Product Type
7.4.3. By Application
7.5. Latin America Small Molecule Targeted Cancer Therapy Demand Share Forecast, 2019-2026
8. Europe Small Molecule Targeted Cancer Therapy Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Europe Average Pricing Analysis
8.2. Europe Small Molecule Targeted Cancer Therapy Market Size and Volume Forecast by Country
8.2.1. Germany
8.2.2. France
8.2.3. Italy
8.2.4. U.K.
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Absolute $ Opportunity Assessment by Country
8.4. Market Attractiveness/Growth Potential Analysis
8.4.1. By Country
8.4.2. By Product Type
8.4.3. By Application
8.5. Europe Small Molecule Targeted Cancer Therapy Demand Share Forecast, 2019-2026
9. Asia Pacific Small Molecule Targeted Cancer Therapy Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Asia Pacific Average Pricing Analysis
9.2. Asia Pacific Small Molecule Targeted Cancer Therapy Market Size and Volume Forecast by Country
9.2.1. China
9.2.2. Japan
9.2.3. South Korea
9.2.4. India
9.2.5. Australia
9.2.6. Rest of Asia Pacific (APAC)
9.3. Absolute $ Opportunity Assessment by Country
9.4. Market Attractiveness/Growth Potential Analysis
9.4.1. By Country
9.4.2. By Product Type
9.4.3. By Application
9.5. Asia Pacific Small Molecule Targeted Cancer Therapy Demand Share Forecast, 2019-2026
10. Middle East & Africa Small Molecule Targeted Cancer Therapy Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Middle East & Africa Average Pricing Analysis
10.2. Middle East & Africa Small Molecule Targeted Cancer Therapy Market Size and Volume Forecast by Country
10.2.1. Saudi Arabia
10.2.2. South Africa
10.2.3. UAE
10.2.4. Rest of Middle East & Africa (MEA)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Market Attractiveness/Growth Potential Analysis
10.4.1. By Country
10.4.2. By Product Type
10.4.3. By Application
10.5. Middle East & Africa Small Molecule Targeted Cancer Therapy Demand Share Forecast, 2019-2026
11. Competition Landscape
11.1. Global Small Molecule Targeted Cancer Therapy Market: Market Share Analysis
11.2. Small Molecule Targeted Cancer Therapy Distributors and Customers
11.3. Small Molecule Targeted Cancer Therapy Market: Competitive Dashboard
11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
11.4.1. Abbott Laboratories
11.4.2. Boehringer Ingelheim GmbH
11.4.3. Bayer HealthCare AG
11.4.4. Cytokinetics Inc.
11.4.5. Hospira Inc.
11.4.6. OncoGenex Pharmaceuticals Inc.
11.4.7. GlaxoSmithKline PLC
The global small molecule targeted cancer therapy market has been segmented on the basis of
Applications
- Small Molecules
- Small Molecule Cyclin-dependent Kinase Inhibitor
- Small Molecule Tyrosine Kinase Inhibitor
- Small Molecule Proteasome Inhibitor
- Monoclonal Antibodies
- Fully Human Antibody
- Chimeric Monoclonal Antibody
- Humanized Monoclonal Antibody
- Humanized Monoclonal Antibody
- Small Molecule Drug Conjugates
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Abbott Laboratories
- Boehringer Ingelheim GmbH
- Bayer HealthCare AG
- Cytokinetics Inc.
- Hospira Inc.
- OncoGenex Pharmaceuticals Inc.
- GlaxoSmithKline PLC
Key players competing in the global small molecule targeted cancer therapy market are Abbott Laboratories; Boehringer Ingelheim GmbH; Bayer HealthCare AG; Cytokinetics Inc.; Hospira Inc.; OncoGenex Pharmaceuticals Inc.; and GlaxoSmithKline PLC. The main market players are continuously engaged in various development activities such as mergers and acquisitions, research and developments, investments for innovative products and collaborations to enhance their market position globally. BeiGene got its cancer drugs in clinic tests, listing poly ADP ribose polymerase inhibitor and a la ibrutinib, BRAF inhibitor.
Our Clients
Related Reports
Some other reports from this category!
